Multicenter, USA - 30 Jan `16Incyte: Topical Ruxolitinib for the Treatment of Vitiligo

Official Title: Topical Ruxolitinib for the Treatment of Vitiligo

In Brief: The purpose of this study is to determine if topical ruxolitinib 1.5% will provide repigmentation in vitiligo lesions.

Description: The hypothesis is that JAK inhibitors can also successfully treat vitiligo. Lesional skin of both alopecia areata and vitiligo primarily contain T cells in a TH1 response as opposed to a mixed cell infiltrate such as in psoriasis or lichen planus. Both alopecia areata and vitiligo are TH1 mediated diseases dependent on the production of IFN-gamma to drive the response. CD8+ T cells are both necessary and sufficient for melanocyte destruction in vitiligo (van den Boorn JG et al 2009) and CD8+NKG2D+ T cells are also necessary and sufficient for hair loss in alopecia areata (Gilhar A et al 2013).

Ages Eligible: 18 Years and older

Start Date: January 2016

Completion Date (estimated): February 2017

Status: Completed

Study ID from ClinicalTrials.gov: NCT02809976 
Other Study ID Numbers: I-18424-15-06 

Location: multicenter, USA

Contact: To learn more about this study, you or your doctor may contact David Rosmarin, MD at Tufts Medical Center. Please refer to this study by its NCT number.

FAQOther Questions

  • What's better: laser or phototherapy?

    In a recent study researchers assessed effect and safety of different laser and phototherapy treatments, such as excimer laser/light, narrowband UVB, UVA and PUVA. No significa...

  • How can I cure vitiligo?

    There is no cure for vitiligo, but there are a number of effective treatment options that can be discussed with your GP or dermatologist. The aim of treatment is to stop new pat...

  • Pyrostegia venusta as a folk medicine for vitiligo?

    Pyrostegia venusta is a neotropical evergreen vine widely spread in Brazil throughout fields, at the coast, edge of the woods and along roadsides (see photo below). Popularly kn...